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Abstract
Atrial fibrillation (AF) is a prominent risk factor for stroke and a leading cause of death and disability throughout Latin America.
Contemporary evidence-based guidelines for the management of AF and stroke incorporate the use of practical and relatively simple
scoring methods to estimate both stroke and bleeding risk, in order to assist in matching patients with appropriate interventions.
This review examines consistencies and differences among guidelines for reducing stroke risk in patients with AF, assessing the role
of user-friendly scoring methods to determine appropriate patients for anticoagulation and other treatment options. Current
options include warfarin and direct oral anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban. These agents have
been found to be superior or noninferior to standard vitamin K antagonist anticoagulation in large randomized trials. Potential
benefits of these agents mainly include lower ischemic stroke rates, reduced intracranial bleeding, no need for regular monitoring,
and fewer drug–drug and drug–food interactions. Expert opinions regarding clinical situations for which data are presently lacking,
such as emergency bleeding and stroke in anticoagulated patients, are also provided. Enhanced attention and adherence to evidence-
based guidelines are essential components for a strategy to reduce stroke morbidity and mortality across Latin America.
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Introduction
Stroke is a leading cause of mortality and disability in Latin
America, although information regarding its epidemiology,
subtypes, and risk factors in the region is limited.1-4 Economic
status, health resources, and habits differ between and within
countries in Latin America, so direct comparisons may be mis-
leading. Stroke prevalence per 1000 people, based on door-to-
door surveys, ranges from 1.7 among rural Bolivians to 7.7
among a predominantly urban Mexican population.5 In a series
of older patients (aged 60 or 65 years), crude prevalence of
stroke ranged from 18.2 per 1000 in Mexico to 46.7 per 1000 in
Colombia,5 and in an Argentine survey, point prevalence of
stroke was 8.7 cases per 1000 inhabitants (4.7 per 1000 age-
adjusted to the worldwide population).6 Incidence rates of
stroke reported in Latin American studies (all adjusted for
Segi’s world population) have included 76.5 annual first-
ever strokes per 100 000 in a 2013 to 2015 Argentine study,7
94 per 100 000 among a predominantly Hispano–Mestizo pop-
ulation in Chile,8 105 per 100 000 in Joinville, Brazil,9 and a
hospitalization rate of 110 per 100 000 for first-ever stroke in
Mexico.10 These incidence rates are in the low-to-average
range of rates seen globally,11 while notably lower rates have
been seen in registry data from locations such as Dijon, France
(57.9 per 100 000)12 and Kurashiki, Japan (60.7 per 100 000).13
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Positive trends have been observed in some areas of Latin
America; the death rate associated with cerebrovascular dis-
ease in Brazil has decreased in recent decades, although stroke
is still a leading cause of death.9,14,15 A clear association
between stroke death and socioeconomic status has been
shown, with mortality rates almost 3 times higher in the lowest
versus highest human development index stratum.16
Atrial fibrillation (AF) is a significant risk factor for stroke,
increasing the risk approximately 5-fold; however, as AF is often
asymptomatic, this figure may be considerably underestimated.17
Data from national health-care systems for 7 Latin American
countries showed a range of prevalence from 1.44% to 1.95% for
AF in the general over-40 population, with nonvalvular AF
(NVAF) accounting for over 85% of cases.18 Prevalence
increases with age, ranging from 2.22% to 2.34% in people aged
60 to 69 years to 8.17% to 8.48% in those aged 80 years.18 In
Brazil alone, an estimated 1.5 million people have AF, with asso-
ciated elevated risks of stroke and heart failure and increased total
mortality.19 In a series of patients with stroke in Brazil, the fre-
quency of AF ranged from 9.5% to 17.5%.1,20,21
Strokes associated with AF are generally more severe and
have worse outcomes than other strokes.22 The Mexican PRE-
MIER registry reported a 30-day poststroke mortality of 22.0%
in patients with AF versus 13.7% in those without; severe dis-
ability followed stroke in 69% of patients with AF versus 52%
without.23-25 In a series of patients with stroke admitted to
tertiary care in São Paulo, the rate of functional independence
at discharge was 60.8% in patients with and 81% in patients
without AF (P < .01).21
The risk of stroke in patients with AF increases with age and
other risk factors, including hypertension, diabetes, heart fail-
ure, and previous stroke. It can be estimated using the scores
from congestive heart failure, hypertension, age 75 y, dia-
betes mellitus, and prior stroke or transient ischemic attack
(CHADS2) or Congestive Heart failure, hypertension, Age
75, Diabetes, Stroke, Vascular disease, Age 65–74, and
Sex-female (CHA2DS2-VASc) (Figure 1).
26-28 The
CHA2DS2-VASc scheme allows a more comprehensive stroke
risk assessment and a greater ability to identify patients at very
low risk who may not require anticoagulation.
Anticoagulation reduces stroke risk in patients with AF.
Vitamin K antagonists (VKAs) reduce the risk of stroke by
approximately 66% and the risk of death by approximately
28% versus no therapy; they are widely prescribed in Latin
America, although perhaps still underused.29,30 Studies have
consistently concluded that the benefit from anticoagulation
significantly exceeds the risks for almost all patients with AF
with a CHADS2 or CHA2DS2-VASc score 2.31,32
Despite the evidence showing its efficacy, anticoagulation is
widely underused. One Mexican study reported that only 35.9%
of patients with a history of AF and recurrent transient ischemic
attack (TIA)/ischemic stroke and 24% of patients with a history
of AF and first-ever TIA/ischemic stroke were receiving oral
anticoagulation with a VKA; of these, only 13.1% and 4.0%,
respectively, were maintained within an optimal therapeutic
range (international normalized ratio [INR]: 2.0-3.0).24,25 In 1
Brazilian study, only 46.5% of eligible patients with AF were
receiving warfarin, with just 15.6% maintained within the opti-
mal INR range.33 In a survey of 7 countries (Argentina, Brazil,
Chile, Colombia, Mexico, Peru, and Venezuela), more than half
of patients with AF were receiving medical treatment but a
significant proportion of patients were not receiving appropriate
anticoagulation despite high stroke risk. Moreover, proportions
of patients with AF receiving treatment within the national
health-care system decreased with increasing age across all
countries.18 Cost and lack of health infrastructure are major
barriers to care.34 Additionally, even appropriate treatment has
limits; an Argentine study found that only 35% of patients with
AF who sustained ischemic strokes had received appropriate
levels of anticoagulation (other stroke etiologies could partially
explain this failure).35
Search Strategy and Selection Criteria
The PubMed database was searched for practice guidelines
concerning stroke prevention in AF published within the last
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Figure 1. Stroke risk in patients with NVAF by 2 common scoring
methods. A, Stroke risk by CHADS2 score in patients with NVAF.
Based on data from Gage et al.26 B, Stroke risk by CHA2DS2-VASc
score in patients with NVAF. Based on data from Lip et al.28 NVAF
indicates nonvalvular atrial fibrillation; TIA, transient ischemic attack.
aPrior myocardial infarction, peripheral artery disease, or aortic
plaque.
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and/or US guidelines, as well as local guidelines, if available.
The authors selected results based on applicability to Latin
America and the practicing neurologist. Supporting evidence
was retrieved based on reference lists for each guideline. Addi-
tional searches were performed to obtain Latin American epi-
demiologic and health-care quality data, as well as clinical trial
data concerning therapies of ongoing research interest that
were published after the most recent guideline updates. As not
all local societies’ publications are indexed on PubMed, Goo-
gle was used to identify additional Latin American guidelines.
A key development that has been reflected in guidelines
over the past 5 years is that additional agents—“novel” direct
oral anticoagulants (DOACs)—have become available. Previ-
ously, oral anticoagulation options were limited to VKAs,
which require frequent monitoring of anticoagulant effect, dose
adjustments, and close attention to diet.36,37 Access barriers to
monitoring, including distance and cost, may help explain why
physicians hesitate to prescribe warfarin for patients with lim-
ited resources.36,37 Aspirin is a widely available alternative but
has consistently and substantially been found less effective in
reducing thromboembolic risk than warfarin in patients with
AF with a CHADS2 score 1.38-40 Vitamin K antagonists are
associated with an increased risk of major bleeding including
intracranial hemorrhage (ICH); indeed, physician concerns
about major bleeding represent a key barrier to optimal anti-
coagulation use in AF. Therefore, assessment of bleeding risk
should be part of patient evaluation before starting anticoagula-
tion. Available scores to assess bleeding risk include the hyper-
tension, abnormal renal/liver function, stroke, bleeding history
or predisposition, labile INR, elderly, drugs/alcohol concomi-
tantly (HAS-BLED) score (Figure 2A).41 The (older age [75þ
years], reduced haemoglobin/haematocrit/history of anaemia,
bleeding history, insufficient kidney function, and treatment
with antiplatelet (ORBIT) bleeding score (older age [75þ years],
reduced haemoglobin/haematocrit/history of anaemia, bleeding
history, insufficient kidney function, and treatment with antipla-
telet) is a new, user-friendly score that may be more widely
applicable than existing schemes (Figure 2B).42
The DOACs dabigatran, rivaroxaban, apixaban, and edox-
aban (approved in the United States, Japan, and Europe) have
predictable pharmacokinetic and pharmacodynamic profiles,
have fewer drug–drug interactions than warfarin, and do not
require regular monitoring. (However, it bears mentioning that
the DOACs are not without potential risk of interactions,
including P-glycoprotein inducers or inhibitors with dabiga-
tran, P-glycoprotein inducers with edoxaban, or dual P-
glycoprotein and strong CYP3A4 inducers or inhibitors with
either rivaroxaban or apixaban.)43-45 The DOAC therapy has
been compared with VKA treatment for reducing the risk of
stroke in patients with NVAF in 4 phase III trials45-50 (and
compared with aspirin in 1 phase III trial51); results are sum-
marized in Table 1. All trials included patients from Latin
America as well as other regions; results from Latin American
subgroups of Randomized Evaluation of Long-Term Anticoa-
gulation Therapy (RE-LY), Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Comparedwith Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation (ROCKET-AF), Effective Anticoagulation
with Factor Xa Next Generation in Atrial Fibrillation–Throm-
bolysis in Myocardial Infarction 48 (ENGAGE AF–TIMI 48),
and Apixaban for Reduction in Stroke and Other Thromboem-
bolic Events in Atrial Fibrillation (ARISTOTLE) are shown in
Table 2. Meta-analysis determined that DOACs reduced stroke
or systemic embolic events versus warfarin (relative risk [RR]
¼ 0.81; P < .0001) while also reducing ICH (RR ¼ 0.48; P <
.0001).52 Although not every guideline includes each one of the
DOACs due to the time of update and the status of evidence for
each DOAC at the time, the agents are included in recommen-
dations from the European Society of Cardiology (ESC), the
ESC branch European Heart Rhythm Association (EHRA), the
American Heart Association/American Stroke Association
(AHA/ASA), the AHA/American College of Cardiology/Heart
Rhythm Society (AHA/ACC/HRS), the American Academy of
Neurology (AAN), the Brazilian Society of Cardiology (BSC),
the Mexican Social Security Institute (MSSI), and the
Argentine Society of Cardiology (ASC).43,44,53-59
Current Guidelines Available for the
Management of Stroke in Patients With AF
Selection of Medical Therapy for Primary
and Secondary Prevention
There is broad acceptance in guidelines of the role of oral
anticoagulant therapy for patients with AF and a CHA2DS2-
VASc score 2. The ESC recommends considering oral antic-
oagulation for women with a CHA2DS2-VASc score of 2 and
men with a CHA2DS2-VASc score of 1, while noting the
importance of balancing the expected stroke reduction with
individual characteristics such as bleeding risk and patient pre-
ference; a strong class I recommendation (indicating evidence
and/or general agreement that the treatment is beneficial, use-
ful, and effective) is made for oral anticoagulation for patients
at higher risk levels. The DOACs and VKAs are both effective
treatment options, with DOACs recommended over VKAs or
aspirin therapy in patients eligible to receive them (class I
recommendation).58
While the ESC guidelines acknowledge the usefulness of
bleeding risk scores such as HAS-BLED, ORBIT, and ABC (age,
biomarkers, clinical history), they do not describe a high bleeding
score as a contraindication for anticoagulation but rather as a
prompt to treat those risk factors that can be corrected.41,42,58,60
The ESC notes that the evidence for stroke prevention with
aspirin is very limited and that antiplatelet therapy cannot be
recommended for stroke prevention in patients with AF.61 The
AHA/ASA recommends oral anticoagulation for primary pre-
vention of stroke in patients with NVAF, a CHA2DS2-VASc
score 2, and an “acceptably low risk” of hemorrhagic com-
plications (class I recommendation, indicating benefit clearly
outweighs risk).55 Clinicians should select from options includ-
ing warfarin (INR: 2.0-3.0), dabigatran, rivaroxaban, and apix-
aban on the basis of patient risk factors (particularly ICH risk),
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cost, tolerability, patient preference, potential for drug–drug
interactions, and other clinical characteristics, including (for
patients taking warfarin) whether a therapeutic INR is consis-
tently maintained. These factors are also to be taken into
account when determining anticoagulation for patients with
NVAF, a CHA2DS2-VASc score of 1, and an acceptably low
risk of hemorrhagic complications (although anticoagulation is
a weaker class IIb recommendation in such patients).
The AHA/ACC/HRS guidelines similarly recommend war-
farin, dabigatran, rivaroxaban, or apixaban in patients with
NVAF and prior stroke or TIA, or a CHA2DS2-VASc score
2, but do not make recommendations for use of the HAS-
BLED or other bleeding scores.44 In the AHA/ASA guidelines
for secondary stroke prevention, VKA therapy (class I; level of
evidence A), apixaban (class I; level of evidence A), and dabi-
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Figure 2. Bleeding risk in patients with NVAF estimated by 2 scoring methods. A, Bleeding risk according to HAS-BLED score. Based on data
from Friberg et al.41 B, Bleeding risk according to ORBIT score. Based on data from O’Brien et al.42 Hct indicates hematocrit; INR, international
normalized ratio; NVAF, nonvalvular atrial fibrillation; OAC, oral anticoagulant.
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prevention of recurrent stroke in patients with paroxysmal or
permanent NVAF. Rivaroxaban is a reasonable choice for such
patients (class IIa; level of evidence B).54
The AAN recommends warfarin, dabigatran, rivaroxaban,
and apixaban to reduce stroke risk in patients with NVAF judged
to require oral anticoagulation; specific recommendations
include warfarin in patients who are well controlled on warfarin
already and dabigatran, rivaroxaban, and apixaban in those with
high risk of ICH or who are unwilling or unable to submit to INR
testing.53 Where oral anticoagulation is unavailable, the AAN
suggests combined aspirin and clopidogrel.
As only dabigatran and rivaroxaban were approved in Brazil
at the time of the 2013 BSC guidelines on antiplatelet and
anticoagulant agents in cardiology, recommendations for the









































Total N 18 113 14 264 21 105 18 201 5599
Latin American
patients (n)



















PP: 1.7 vs 2.2, RRR























2.1 vs 2.4, RRR ¼
12%, P ¼ .12,














1.6 vs 3.7, RRR ¼
55%, P < .001
























RRR ¼ 8%, P
¼ .42
1.1 vs 3.0, RRR ¼























0.2 vs 0.3, RRR ¼























3.5 vs 4.4, RRR ¼
21%, P ¼ .07
Safety




RRR ¼ 6%, P
¼ .41
SOT: 3.6 vs 3.4,












31%, P < .001
1.4 vs 1.2, RRI ¼
13%, P ¼ .57,
SOT: 1.4 vs 0.9,























58%, P < .001
0.4 vs 0.4, RRR ¼
15%, P ¼ .69
Abbreviations: BID, twice daily; DOAC, direct oral anticoagulant; INR, international normalized ratio; ITT, intent to treat; mITT, modified intent to treat; NVAF,
nonvalvular atrial fibrillation; OT, on treatment; PP, per protocol; QD, once daily; RRI, relative risk increase; RRR, relative risk reduction; SOT, safety on-
treatment.
aBoth RRRs and RRIs are calculated from the published hazard ratios for ROCKET AF, ENGAGE AF–TIMI 48, ARISTOTLE, and AVERROES and from the
published relative risks from RE-LY. All columns show DOAC versus warfarin, except AVERROES, which compared apixaban with aspirin. All data are presented
as annual rates per 100 patients, except as noted. All analyses were performed on ITT populations unless otherwise specified. Adapted with permission of Dove
Medical Press Ltd, from Foody JM. Clin Int Aging. 2017;12:175-187; permission conveyed through Copyright Clearance Center, Inc.
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use of DOACs in patients with NVAF are limited to these
agents. Anticoagulation is recommended in patients with a
CHA2DS2-VASc score 2, and anticoagulation or aspirin is
recommended in patients with a CHA2DS2-VASc score of 1;
dabigatran and rivaroxaban are described as alternatives to
warfarin in patients needing anticoagulation.56 Similarly, the
ASC guidelines offer recommendations on the use of dabiga-
tran and rivaroxaban, with the additional option of apixaban.59
Brazilian guidelines note that selection of antithrombotic ther-
apy should be based on risk of embolic events as per
CHA2DS2-VASc score and risk of bleeding as per HAS-
BLED and based on RR benefit for each individual patient,
particularly among individuals. The MSSI guidelines, pub-
lished in 2012, mention only dabigatran and identify it as an
alternative to VKA.57
Emergency Bleeding
Although the short half-life of DOACs may decrease the need
for immediate reversal, in cases of urgent bleeding or overdose,
warfarin may have a perceived advantage as its activity can be
reversed by vitamin K. The dabigatran antidote idarucizumab
has recently become available in the United States,62 and phase
III trials of andexanet alfa for reversal of apixaban and rivar-
oxaban have been published63; aripazine, an agent for reversal
of all DOACs, is also in development.64 It should be noted that
onset of vitamin K reversal of warfarin’s anticoagulant effects
may take hours after infusion; sometimes over a day is needed
for an effective response.43,65 In cases of major bleeding related
to VKA administration, prothrombin complex concentrate
(PCC) may be required in addition to vitamin K (fresh frozen
plasma is another strategy but is associated with potential aller-
gic reaction or infection and with longer time to prepare; more
evaluation is needed for the use of recombinant factor
VIIa).43,66 The AHA/ASA note the limitations of warfarin’s
purported advantages in reversal, citing the high mortality rates
of warfarin-related ICH despite the availability of reversal
agents.55 The 2015 EHRA practical guide43 aligns with the
ESC recommendations for anticoagulation in patients with
NVAF, with specific practical clinical scenarios such as the
need for emergency reversal.43 The EHRA practical guide
advises consideration of PCC or activated PCC (aPCC) for
emergency reversal of bleeding in a patient who has taken a
DOAC (or idarucizumab, if available, for a patient who has
taken dabigatran).43
The BSC guidelines indicate that PCC can be used to
reverse the activity of factor Xa inhibitors.56 Prothrombin com-
plex concentrate and aPCC are available in Latin American
countries for anticoagulation reversal; however, because of
their higher cost versus fresh frozen plasma, they are not rou-
tinely used, especially in public hospitals.67 The ASC guide-
lines note that prothrombin factor complex has been found to
restore coagulation in patients treated with rivaroxaban, but not
those treated with dabigatran (while not making a formal rec-
ommendation for reversing DOAC-induced anticoagulation).59
Compared with VKAs, the risk of ICH with DOACs is
reduced, but not eliminated, and ICH is still associated with
high rates of death and disability.52,68,69 Because patients with
AF who survive ICH continue to have increased risk of
ischemic stroke,41 clinicians are tasked with weighing the
risk–benefit of resuming or discontinuing oral anticoagulation
therapy for anticoagulated patients presenting with ICH.
Nielsen et al identified patients with AF receiving warfarin
or a DOAC with incident ICH.70 In 1752 patients, after 1 year
since the ICH, the rate of ischemic stroke/systemic embolism
(SE) and all-cause mortality (per 100 person-years) was 13.6
for oral anticoagulation-treated patients compared with 27.3 for
untreated patients and 25.7 for patients receiving antiplatelets;
the adjusted hazard ratio (HR) for the combined end point of
ischemic stroke/SE and all-cause mortality was 0.55 (95%
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confidence interval: 0.39-0.78) for oral anticoagulation versus
no treatment. The EHRA considers that DOACs may be
restarted 4 to 8 weeks after an ICH, if the risk of another ICH
is considered to be low and cardioembolic risk is high.43 The
BSC guidelines advocate restarting anticoagulation 10 to 30
weeks after an event of acute cerebral hemorrhage.56
Analyses from RE-LY showed similar ICH distributions
across anatomic sites between dabigatran and warfarin, while
absolute rates at all sites and fatal and traumatic ICH rates were
lower for dabigatran.71 However, direct comparisons of
DOACs versus warfarin following ICH are lacking. A trial
assessing apixaban versus no anticoagulation in patients with
AF and recent ICH during anticoagulation treatment is
ongoing.72
Treatment Interruption
Although the need for a temporary cessation of anticoagula-
tion is quite common (in large clinical trials of DOACs
versus warfarin, approximately one-quarter to one-third of
patients required such cessation), guidelines offer inconsis-
tent recommendations for its management.73,74 The EHRA
practical guide recommends that apixaban, edoxaban, and
rivaroxaban be stopped 48 hours before elective surgery
in those undergoing procedures with high bleeding risk and
24 hours before in those undergoing procedures with low
bleeding risk (36 hours before in case of creatinine clear-
ance [CrCl]15-30 mL/min). In those undergoing procedures
with low bleeding risk, dabigatran should be stopped 24,
36, and 48 hours beforehand in those with CrCl 80
mL/min, 50 to 80 mL/min, and 30 to 50 mL/min, respectively
(dabigatran is not indicated in patients with CrCl 15-30 mL/
min); these times are doubled for procedures with high bleeding
risk. The EHRA does not recommend bridging therapy with
another anticoagulant.43 This contrasts with the AHA/ASA,
who note the possibility of increased risk of stroke after abrupt
discontinuation of the DOACs and thus recommend consider-
ation of bridging therapy for those taking a DOAC, as well as
recommending bridging for those taking VKA at high risk of
thromboembolism and considering bridging for those at moder-
ate risk.54 The AHA/ACC/HRS guidelines acknowledge the
lack of data but regard bridging therapy with heparin in
those at high thromboembolic risk who are taking a VKA
to be common practice, while DOACs can be simply with-
held for 1 day before the procedure.44 Brazilian guidelines
recommend bridging therapy with heparin in patients taking
VKA for whom cardiac surgery is planned (with disconti-
nuation of unfractionated heparin 4 hours before or low-
molecular-weight heparin 24 hours before in those at high
risk of thromboembolism). In those with normal renal func-
tion undergoing cardiac surgery, dabigatran should be dis-
continued 48 hours before surgery (24 hours before a
procedure with low bleeding risk) and rivaroxaban 24 hours
before surgery, with no bridging therapy recommended in
either case.56 The ESC holds that most cardiovascular inter-
ventions can be safely performed without interrupting
anticoagulation and that when interruption is necessary brid-
ging therapy is not beneficial in patients without mechanical
heart valves.58 The ASC guidelines identify bridging ther-
apy with heparin as a reasonable strategy for those being
treated with a VKA; administration of dabigatran should be
suspended 24 hours before surgery in those with CrCl
>50 mL/min and 2 to 5 days beforehand in those with CrCl
<50 mL/min, while rivaroxaban and apixaban should be
suspended 24 hours before surgery.59
Management of Acute Ischemic Stroke
in Anticoagulated Patients
Despite the benefits of VKAs and DOACs to reduce stroke in
patients with AF, approximately 1.0% to 2.0% of treated
patients are still likely to experience an acute ischemic stroke
each year.45-48,50,51
Thrombolytic therapy with recombinant tissue-type plasmi-
nogen activator is appropriate when given shortly after the onset
of ischemic stroke (4.5 hours).43 However, current anticoagu-
lation is a contraindication to thrombolysis. Clinicians must
determine the patient’s current anticoagulation status and esti-
mate any corresponding increase in the risk of hemorrhage with
reperfusion. Clinically important anticoagulant effect can be
ruled out by detecting normal values on the thrombin time or
ecarin clotting time, the Hemoclot Thrombin Inhibitor assay,
4 hours after the last dose of dabigatran, or a normal antifactor
Xa assay 5 hours after the last dose of rivaroxaban or
apixaban.75 Absent reliable point-of-care tests, the EHRA
recommends avoiding thrombolysis in patients who have
received DOAC therapy within 24 to 48 hours or in whom there
is uncertainty regarding anticoagulation status; however, this
recommendation is arbitrary and untested.43
Recent clinical trial evidence has shown that arterial throm-
bectomy can be an effective treatment for patients with acute
ischemic stroke with large artery occlusions.76-80 These trials,
unlike previous evaluations of endovascular therapy, tested the
addition of the endovascular approach to standard intravenous
thrombolysis, required documentation of occlusion, had low
median onset-to-groin times, and generally employed stent
retrievers that were able to achieve faster and more complete
recanalization. Recent investigation has found no increased
risk of symptomatic ICH associated with the use of oral antic-
oagulants among patients undergoing arterial thrombectomy.81
Thus, this approach may be an option in patients with acute
ischemic stroke who are receiving oral anticoagulants.
With no prospective data indicating the ideal time to resume
anticoagulation after ischemic stroke, the decision is largely
based on clinical judgment. The EHRA practical guide advises
that DOAC continuation after ischemic stroke is linked to
infarct volume.43 If the infarct size is unlikely to increase the
risk of early secondary intracerebral bleeding, DOAC use is
similar to usual practice with VKAs. While acknowledging the
lack of data, the guidelines mention the 1-3-6-12-day principle,
which advises resumption of anticoagulation after 1 day fol-
lowing a TIA; 3 days following a small, nondisabling infarct; 5
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to 7 days following a moderate stroke; and 12 to 14 days after a
large infarct.43 The AHA/ASA guidelines recommend initiat-
ing anticoagulation within 14 days after the onset of neurologic
symptoms (class IIa; level of evidence B).54 The BSC guide-
lines recommend antiplatelet therapy for secondary prevention
of noncardioembolic ischemic stroke.56
Left Atrial Appendage Closure
The ESC recommends left atrial appendage closure only for
those patients in whom anticoagulation is contraindicated, cit-
ing limited evidence comparing this approach to anticoagula-
tion.58 A meta-analysis cited in the guidelines including 2406
patients with NVAF found reduced rates of hemorrhagic
strokes (HR ¼ 0.22; P ¼ .004), cardiovascular/unexplained
death (HR ¼ 0.48; P ¼ .006), and nonprocedural bleeding
(HR ¼ 0.51; P ¼ .006) with the WATCHMAN device versus
warfarin, although the increased ischemic stroke rate with the
device meant a similar event rate for all-cause stroke or SE (HR
¼ 1.02; P ¼ .94).82 The AHA/ASA guidelines recommend left
atrial appendage closure for consideration in high-risk patients
with AF deemed unsuitable for anticoagulation who can toler-
ate the risk of 45 days periprocedural anticoagulation, if per-
formed at a center with low rates of complications. Support for
this position comes from the results of the WATCHMAN trial,
which found noninferiority of the WATCHMAN device versus
warfarin in the primary efficacy end point of stroke/SE/cardi-
ovascular death, as well as the lack of comparison with
DOACs.55 The AHA/ACC/HRS guidelines make no recom-
mendation regarding this approach.44 The ASC guidelines
describe left arterial appendage closure as reasonable in




Nonadherence to guidelines is associated with poor outcomes
in anticoagulant therapy.83 In the analysis from ROCKET AF,
the individual-level time in therapeutic range for patients in the
warfarin group was significantly lower in Latin America than
in the United States/Canada.84 Concerns regarding the safety of
standard anticoagulation may be a factor; 1 Brazilian study of
patients in the oral anticoagulation outpatient clinic at a cardi-
ology hospital found that 68.6% were concerned about the
bleeding risk associated with oral VKAs.85 Aspirin, mean-
while, may be overused in the region; a literature search found
that antiplatelet therapy was prescribed to 63% of patients with
AF in Argentina and Mexico.86 Encouraging signs of progress
may be seen with greater attention to adherence. An examina-
tion of quality indicators at 1 Brazilian primary stroke center
found higher use of some appropriate acute interventions ver-
sus those seen in the US-based Get with the Guidelines
(GWTG) program, such as intravenous thrombolysis given to
eligible patients (69.5% vs 42.1% in the GWTG cohort in 2003
and 72.8% in the GWTG 2007 data set).87 Notably, patients in
the Brazilian center were more likely to receive anticoagulation
for AF if followed by a neurologist during admission. Creation
of a prospective stroke registry using a standardized form filled
out by the neurology resident in charge during hospitalization
was found to improve adherence to measures of acute stroke
care quality in a Mexican study.88 Younger physicians may be
more attuned to guideline recommendations; a survey of car-
diologists in Rio Grande do Sul, Brazil, found that 87.7% of
those having graduated less than 25 years ago used a risk score
to determine the need for anticoagulation versus 73.2% of those
who had graduated over 25 years ago (P ¼ .02).89
Adherence to guidelines can be limited by cost/access
issues, which vary across the region.90 In Brazil, patients
treated in the public sector typically continue to receive war-
farin or another VKA because these costs are supported by the
public system. Only 30% of patients have private health insur-
ance and access to newer therapies (eg, DOACs) for stroke
prevention. In Brazil and Mexico, local authorities may sub-
sidize more expensive medications, but it takes time to get new
therapies included on formularies and differences in access
exist between local areas.91
Conclusions
Both AF and stroke are substantial and impactful health prob-
lems in Latin America. Although variations in access to health
care may play a role, there is ample room for improvement
through greater adherence to evidence-based treatment recom-
mendations. The CHA2DS2-VASc and HAS-BLED (and prob-
ably ORBIT) scores offer both predictive value and relative
simplicity and can be used together to ensure appropriate antic-
oagulation therapy for patients able to benefit from it. Although
more data are needed regarding the best approaches for specific
clinical situations, such as emergency bleeding and stroke in
patients who are being anticoagulated with DOACs, these
agents offer the promise of treatment without routine monitor-
ing that may help toward meeting the goal of all appropriate
patients receiving anticoagulation.
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